11:42 AM EST - Immunovaccine Inc. : Announced new data from its Phase 1/1b trial in ovarian cancer, which reinforced previously reported results showing that DPX-Survivac was well tolerated, with no unexpected treatment-related serious adverse events (SAEs) and that it demonstrated the ability to generate a relevant, sustained immune response. Immunovaccine Inc.
shares T.IMV are trading up $0.02 at $0.60.
